HRP20231156T1 - Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka - Google Patents
Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka Download PDFInfo
- Publication number
- HRP20231156T1 HRP20231156T1 HRP20231156TT HRP20231156T HRP20231156T1 HR P20231156 T1 HRP20231156 T1 HR P20231156T1 HR P20231156T T HRP20231156T T HR P20231156TT HR P20231156 T HRP20231156 T HR P20231156T HR P20231156 T1 HRP20231156 T1 HR P20231156T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- antibody
- seq
- antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 239000012634 fragment Substances 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000004614 tumor growth Effects 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- -1 cancer vaccine Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 229940125555 TIGIT inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 231100000001 growth retardation Toxicity 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Antitijelo ili njegov fragment koji se veže za antigen koji specifično veže programiranu staničnu smrt 1 (PD-1) za upotrebu u postupku liječenja B-staničnog ne-Hodgkinovog limfoma u kombinaciji s bispecifičnim antitijelom koje sadrži prvi krak koji se veže za antigen i koji specifično veže CD20 i drugi krak koji se veže za antigen koji specifično veže CD3, pri čemu navedeni postupak obuhvaća davanje subjektu kome je to potrebno terapeutski efikasne količine svakog antitijela ili fragmenta, pri čemu:
anti-PD-1 antitijelo ili njegov fragment koji se veže za antigen sadrži tri regije koje određuju komplementarnost teškog lanca (CDR) (HCDR1, HCDR2 i HCDR3) i tri CDR lakog lanca (LCDR1, LCDR2 i LCDR3), pri čemu HCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 3; HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 4; HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 5; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 6; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 7; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 8;
prvi krak bispecifičnog antitijela koji se veže za antigen obuhvaća tri regije koje određuju komplementarnost teškog lanca (CDR) (A-HCDR1, A-HCDR2 i A-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu A-HCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 14; A-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO:15; A-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 16; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19;
drugi krak bispecifičnog antitijela koji se veže za antigen sadrži tri CDR teška lanca (B-HCDR1, B-HCDR2 i B-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu B-HCDR1 sadrži aminokiselinsku sekvencu od SEQ ID NO: 20; B-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 21; B-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 22; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19; i
svaka doza anti-PD-1 antitijela sadrži 0.1 do 20 mg/kg tjelesne težine subjekta.
2. Bispecifično antitijelo koje sadrži prvi krak koji se veže za antigen koji specifično veže CD20 i drugi krak koji se veže za antigen koji specifično veže CD3 za upotrebu u postupku liječenja B-staničnog ne-Hodkinovog limfoma u kombinaciji s antitijelom ili njegovim fragmentom koji veže antigen koji specifično veže programiranu staničnu smrt 1 (PD-1), spomenuti postupak obuhvaća davanje subjektu kome je to potrebno terapeutski efikasne količine svakog antitijela ili fragmenta, pri čemu:
anti-PD-1 antitijelo ili njegov fragment koji se veže za antigen sadrži tri regije koje određuju komplementarnost teškog lanca (CDR) (HCDR1, HCDR2 i HCDR3) i tri CDR lakog lanca (LCDR1, LCDR2 i LCDR3), pri čemu HCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 3; HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 4; HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 5; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 6; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 7; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 8;
prvi krak bispecifičnog antitijela koji se veže za antigen obuhvaća tri regije koje određuju komplementarnost teškog lanca (CDR) (A-HCDR1, A-HCDR2 i A-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu A-HCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 14; A-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO:15; A-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 16; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19;
drugi krak bispecifičnog antitijela koje se veže za antigen sadrži tri CDR teška lanca (B-HCDR1, B-HCDR2 i B-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu B-HCDR1 sadrži aminokiselinsku sekvencu od SEQ ID NO: 20; B-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 21; B-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 22; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19; i
svaka doza anti-PD-1 antitijela sadrži 0-1 do 20 mg/kg tjelesne težine subjekta.
3. Farmaceutski sastav za upotrebu u postupku liječenja B-staničnog ne-Hodgkinovog limfoma, pri čemu spomenuta kompozicija sadrži antitijelo ili njegov fragment koji se veže za antigen koji specifično veže programiranu staničnu smrt 1 (PD-1) i bispecifično antitijelo koje sadrži prvi antigen koji se veže krak koji specifično veže CD20 i drugi krak koji se veže za antigen koji specifično veže CD3, pri čemu:
anti-PD-1 antitijelo ili njegov fragment koji se veže za antigen sadrži tri regije koje određuju komplementarnost teškog lanca (CDR) (HCDR1, HCDR2 i HCDR3) i tri CDR lakog lanca (LCDR1, LCDR2 i LCDR3), pri čemu HCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 3; HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 4; HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 5; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 6; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 7; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 8;
prvi krak bispecifičnog antitijela koji se veže za antigen sadrži tri CDR teška lanca (A-HCDR1, A-HCDR2 i A-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu A-HCDR1 sadrži aminokiselinsku sekvencu od SEQ ID NO: 14; A-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 15; A-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 16; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19;
drugi krak bispecifičnog antitijela koji se veže za antigen sadrži tri CDR teška lanca (B-HCDR1, B¬HCDR2 i B-HCDR3) i tri CDR laka lanca (LCDR1, LCDR2 i LCDR3), pri čemu B-HCDR1 sadrži aminokiselinsku sekvencu od SEQ ID NO: 20; B-HCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 21; B-HCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 22; LCDR1 sadrži aminokiselinsku sekvencu SEQ ID NO: 17; LCDR2 sadrži aminokiselinsku sekvencu SEQ ID NO: 18; i LCDR3 sadrži aminokiselinsku sekvencu SEQ ID NO: 19; i
kompozicija sadrži 0.05 do 600 mg anti-PD-1 antitijela.
4. Antitijelo ili antigen-vezujući fragment, koje specifično veže PD-1 za upotrebu prema zahtjevu 1 ili bispecifično antitijelo za upotrebu prema zahtjevu 2, pri čemu:
(a) svaka doza anti-PD-1 antitijela sadrži 0.3, 1, 3, ili 10 mg/kg telesne težine subjekta; ili
(b) svaka doza anti-PD-1 antitijela sadrži 0.05 do 600 mg.
5. Antitijelo, antigen-vezujući fragment ili bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1, 2 ili 4, pri čemu:
(a) svaka doza bispecifičnog antitijela sadrži 0,1 do 10 mg/kg tjelesne težine subjekta; ili
(b) svaka doza bispecifičnog antitijela sadrži 10 do 8000 mikrograma, opcionalno pri čemu svaka doza anti-PD-1 antitijela sadrži 1, 3 ili 10 mg/kg i svaka doza bispecifičnog antitijela sadrži 30, 100, 300, 1000 ili 2000 mikrograma.
6. Antitijelo, antigen-vezujući fragment ili bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1, 2, 4 ili 5, pri čemu:
(a) svaka doza anti-PD-1 antitijela se primjenjuje 0,5 -12 tjedana neposredno nakon prethodne doze;
(b) svaka doza bispecifičnog antitijela se primjenjuje 0,5 -12 tjedana neposredno nakon prethodne doze, opcionalno pri čemu se svaka doza anti-PD-1 antitijela primjenjuje jednom u dva tjedna ili jednom u tri tjedna, a svaka doza antitijela na PD-1 bispecifično antitijelo se primjenjuje jednom tjedno; i/ili
(c) svaka doza bispecifičnog antitijela se dijeli na 2-5 frakcija u periodu doziranja.
7. Antitijelo, antigen-vezujući fragment ili bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1, 2, 4, 5 ili 6, pri čemu je anti-PD-1 antitijelo davano prije, istovremeno s ili nakon bispecifičnog antitijela, opcionalno gdje je anti-PD-1 antitijelo davano prije bispecifičnog antitijela, kao što je gdje anti-PD-1 antitijelo je davano 1 tjedan prije bispecifičnog antitijela.
8. Antitijelo, antigen-vezujući fragment ili bispecifično antitijelo ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-7, pri čemu su antitijela davana intravenski, potkožno, ili intraperitonealno.
9. Antitijelo, antigen-vezujući fragment, bispecifično antitijelo ili farmaceutska kompozicija za upotrebu prema bilo kojem od zahtjeva 1-8, pri čemu:
(a) subjekt je rezistentan ili neadekvatno reagira na, ili je relapsirao nakon prethodne terapije;
(b) tretman proizvodi terapeutski efekt izabran iz grupe koja se sastoji od usporavanja rasta tumora, smanjenja broja tumorskih stanica, regresije tumora, povećanja preživljavanja, djelomičnog odgovora i potpunog odgovora, opcionalno pri čemu je rast tumora odgođen za najmanje 10 dana u usporedbi sa neliječenim subjektom; i/ili
(c) rast tumora je inhibiran za najmanje 10% u usporedbi s neliječenim subjektom, ili je rast tumora inhibiran za najmanje 10% u usporedbi sa subjektom koji je primijenjen s bilo kojim antitijelom kao monoterapija.
10. Antitijelo, antigen-vezujući fragment ili bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1, 2, 4, 5 ili 6, pri čemu se anti-PD-1 antitijelo daje prije bispecifičnog antitijela i tumorski rast je inhibiran za najmanje 20% u usporedbi sa subjektom kome je davano bispecifično anti-CD20/anti-CD3 antitijelo prije anti-PD-1 antitijela.
11. Antitijelo, antigen-vezujući fragment, bispecifično antitijelo ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-10, dalje koji obuhvaća davanje subjektu trećeg terapeutskog agensa ili terapije, pri čemu je treći terapeutski agens ili terapija odabran iz grupe koja se sastoji iz zračenja, kirurgije, kemoterapeutskog sredstva, cjepiva protiv raka, PD-L1 inhibitora, LAG-3 inhibitora, CTLA-4 inhibitora, TIM3 inhibitora, BTLA inhibitora, TIGIT inhibitora, CD47 inhibitora, inhibitora indoleamin- 2,3-dioksigenaze (IDO), antagonista vaskularnog endotelnog faktora rasta (VEGF), inhibitora angiopoetina-2 (Ang2), inhibitora transformirajućeg faktora rasta beta (TGFb), inhibitora receptora epidermalnog faktora rasta (EGFR), antitijela na tumor-specifični antigen, cjepivo Bacillus Calmette-Guerin, faktora stimulacije kolonije granulocita-makrofaga, citotoksina, inhibitora receptora interleukina 6 (IL-6R), inhibitora receptora interleukina 4 (IL-4R), IL- 10 inhibitora, IL-2, IL-7, IL-21, IL-15, konjugata antitijelo-lek, antiinflamatornog lijeka i dijetetskog suplementa.
12. Antitijelo, antigen-vezujući fragment, bispecifično antitijelo ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-11, pri čemu anti-PD-1 antitijelo ili njegov fragment za vezanje antigena sadrži:
(a) varijabilnu regiju teškog lanca (HCVR) koji sadrži aminokiselinsku sekvencu SEQ ID NO: 1 i varijabilnu regiju lakog lanca (LCVR) koji sadrži aminokiselinsku sekvencu SEQ ID NO: 2; ili
(b) težak lanac koji sadrži aminokiselinsku sekvencu SEQ ID NO: 9 i laki lanac koji sadrži aminokiselinsku sekvencu SEQ ID NO: 10.
13. Antitijelo, antigen-vezujući fragment, bispecifično antitijelo, ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-12, pri čemu:
drugi krak za vezivanje antigena bispecifičnog antitijela sadrži A-HCVR koji sadrži aminokiselinsku sekvencu SEQ ID NO: 11 i LCVR koji sadrži aminokiselinsku sekvencu SEQ ID NO: 12.
14. Antitijelo, antigen-vezujući fragment, bispecifično antitijelo ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-13, pri čemu drugi krak za vezanje antigena bispecifičnog antitijela sadrži B-HCVR koji sadrži aminokiselinsku sekvencu SEQ ID NO: 13 i LCVR koji sadrži aminokiselinsku sekvencu SEQ ID NO: 12.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270749P | 2015-12-22 | 2015-12-22 | |
| EP16826557.7A EP3394103B1 (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
| PCT/US2016/068030 WO2017112775A1 (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231156T1 true HRP20231156T1 (hr) | 2024-01-05 |
Family
ID=57799835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231156TT HRP20231156T1 (hr) | 2015-12-22 | 2016-12-21 | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20170174779A1 (hr) |
| EP (1) | EP3394103B1 (hr) |
| JP (1) | JP7126941B2 (hr) |
| KR (1) | KR20180089444A (hr) |
| CN (1) | CN108473578A (hr) |
| AU (1) | AU2016378721B2 (hr) |
| BR (1) | BR112018012801B1 (hr) |
| CA (1) | CA3009161A1 (hr) |
| DK (1) | DK3394103T3 (hr) |
| EA (1) | EA201891428A1 (hr) |
| ES (1) | ES2954153T3 (hr) |
| FI (1) | FI3394103T3 (hr) |
| HK (1) | HK1255040A1 (hr) |
| HR (1) | HRP20231156T1 (hr) |
| HU (1) | HUE063377T2 (hr) |
| IL (1) | IL259924A (hr) |
| LT (1) | LT3394103T (hr) |
| MA (1) | MA44146B1 (hr) |
| MD (1) | MD3394103T2 (hr) |
| MX (1) | MX2018007613A (hr) |
| PL (1) | PL3394103T3 (hr) |
| PT (1) | PT3394103T (hr) |
| RS (1) | RS64588B1 (hr) |
| SG (2) | SG11201804765UA (hr) |
| SI (1) | SI3394103T1 (hr) |
| WO (1) | WO2017112775A1 (hr) |
| ZA (1) | ZA201804681B (hr) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| RU2767357C2 (ru) | 2016-06-14 | 2022-03-17 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
| CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| CN109641050A (zh) | 2016-08-16 | 2019-04-16 | 里珍纳龙药品有限公司 | 用于对混合物中的个体抗体进行量化的方法 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
| CN109923411B (zh) | 2016-10-25 | 2022-05-31 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| WO2018099539A1 (en) * | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| EP3630180A1 (en) | 2017-06-01 | 2020-04-08 | Compugen Ltd. | Triple combination antibody therapies |
| KR20200014304A (ko) * | 2017-06-02 | 2020-02-10 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체 |
| CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
| WO2019028316A1 (en) * | 2017-08-03 | 2019-02-07 | Amgen Inc. | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| CA3075927A1 (en) * | 2017-09-20 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| EP3746117A1 (en) * | 2018-01-31 | 2020-12-09 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| TW202005985A (zh) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 |
| TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| EP4270009A3 (en) | 2018-10-31 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| MA55084A (fr) | 2019-02-28 | 2022-01-05 | Regeneron Pharma | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
| MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
| EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
| BR112021025438A2 (pt) | 2019-12-06 | 2022-06-21 | Regeneron Pharma | Composições de proteínas anti-vegf e métodos para produzir as mesmas |
| CN114929343A (zh) * | 2019-12-06 | 2022-08-19 | 瑞泽恩制药公司 | 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022072762A1 (en) * | 2020-10-02 | 2022-04-07 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| WO2022165266A1 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN114133449A (zh) * | 2021-12-14 | 2022-03-04 | 厦门大学附属第一医院 | 一种检测淋巴细胞表面pd-1受体的抗体组合物及其应用 |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| BR122021025087B1 (pt) * | 2013-12-17 | 2023-04-04 | Genentech, Inc | Anticorpo anti-cd3, célula hospedeira procariótica, método de produção do anticorpo biespecífico, imunoconjugado, composição, uso do anticorpo biespecífico e kit |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-12-21 CA CA3009161A patent/CA3009161A1/en active Pending
- 2016-12-21 US US15/386,453 patent/US20170174779A1/en not_active Abandoned
- 2016-12-21 JP JP2018532781A patent/JP7126941B2/ja active Active
- 2016-12-21 PT PT168265577T patent/PT3394103T/pt unknown
- 2016-12-21 ES ES16826557T patent/ES2954153T3/es active Active
- 2016-12-21 CN CN201680075172.2A patent/CN108473578A/zh active Pending
- 2016-12-21 WO PCT/US2016/068030 patent/WO2017112775A1/en active Application Filing
- 2016-12-21 FI FIEP16826557.7T patent/FI3394103T3/fi active
- 2016-12-21 PL PL16826557.7T patent/PL3394103T3/pl unknown
- 2016-12-21 MX MX2018007613A patent/MX2018007613A/es unknown
- 2016-12-21 BR BR112018012801-5A patent/BR112018012801B1/pt active IP Right Grant
- 2016-12-21 HR HRP20231156TT patent/HRP20231156T1/hr unknown
- 2016-12-21 SG SG11201804765UA patent/SG11201804765UA/en unknown
- 2016-12-21 KR KR1020187017751A patent/KR20180089444A/ko active Search and Examination
- 2016-12-21 DK DK16826557.7T patent/DK3394103T3/da active
- 2016-12-21 LT LTEPPCT/US2016/068030T patent/LT3394103T/lt unknown
- 2016-12-21 MD MDE20181060T patent/MD3394103T2/ro unknown
- 2016-12-21 HU HUE16826557A patent/HUE063377T2/hu unknown
- 2016-12-21 EA EA201891428A patent/EA201891428A1/ru unknown
- 2016-12-21 AU AU2016378721A patent/AU2016378721B2/en active Active
- 2016-12-21 RS RS20230829A patent/RS64588B1/sr unknown
- 2016-12-21 SG SG10202005670TA patent/SG10202005670TA/en unknown
- 2016-12-21 MA MA44146A patent/MA44146B1/fr unknown
- 2016-12-21 EP EP16826557.7A patent/EP3394103B1/en active Active
- 2016-12-21 SI SI201631733T patent/SI3394103T1/sl unknown
-
2018
- 2018-06-10 IL IL259924A patent/IL259924A/en unknown
- 2018-07-13 ZA ZA2018/04681A patent/ZA201804681B/en unknown
- 2018-11-06 HK HK18114163.2A patent/HK1255040A1/zh unknown
-
2021
- 2021-03-24 US US17/210,860 patent/US20210214457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2954153T3 (es) | 2023-11-20 |
| MA44146B1 (fr) | 2023-10-31 |
| HK1255040A1 (zh) | 2019-08-02 |
| CN108473578A (zh) | 2018-08-31 |
| MA44146A (fr) | 2018-10-31 |
| EP3394103B1 (en) | 2023-06-28 |
| LT3394103T (lt) | 2023-09-11 |
| MD3394103T2 (ro) | 2023-11-30 |
| IL259924A (en) | 2018-07-31 |
| WO2017112775A1 (en) | 2017-06-29 |
| US20210214457A1 (en) | 2021-07-15 |
| MX2018007613A (es) | 2018-09-21 |
| KR20180089444A (ko) | 2018-08-08 |
| PL3394103T3 (pl) | 2023-11-20 |
| CA3009161A1 (en) | 2017-06-29 |
| AU2016378721B2 (en) | 2024-01-11 |
| FI3394103T3 (fi) | 2023-08-30 |
| BR112018012801A2 (pt) | 2018-12-04 |
| AU2016378721A1 (en) | 2018-07-19 |
| PT3394103T (pt) | 2023-09-04 |
| SG11201804765UA (en) | 2018-07-30 |
| RS64588B1 (sr) | 2023-10-31 |
| EP3394103A1 (en) | 2018-10-31 |
| EA201891428A1 (ru) | 2018-12-28 |
| SI3394103T1 (sl) | 2023-10-30 |
| JP2019503361A (ja) | 2019-02-07 |
| BR112018012801B1 (pt) | 2024-03-12 |
| JP7126941B2 (ja) | 2022-08-29 |
| DK3394103T3 (da) | 2023-09-04 |
| HUE063377T2 (hu) | 2024-01-28 |
| US20170174779A1 (en) | 2017-06-22 |
| SG10202005670TA (en) | 2020-07-29 |
| ZA201804681B (en) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2019515008A5 (hr) | ||
| JP2022050618A5 (hr) | ||
| JP2019519499A5 (hr) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018534933A5 (hr) | ||
| JP2008540447A5 (hr) | ||
| CN110248668B (zh) | 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| JP2020508317A5 (hr) | ||
| TW202228777A (zh) | 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法 | |
| JP2017501157A5 (hr) | ||
| JP2013542194A5 (hr) | ||
| RU2018131237A (ru) | Способы лечения атопического дерматита с помощью антагониста il-4r | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| IL308805A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020515577A5 (hr) | ||
| JP2020502147A5 (hr) | ||
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| JPWO2019246514A5 (hr) |